C12N 2720/12221
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2720/12221 (Viruses as such) appears on 13 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 17
- Assignees
- 9
- Inventors
- 32
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 3 |
| 2019 | 0 | 1 |
| 2020 | 2 | 2 |
| 2021 | 1 | 2 |
| 2022 | 1 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Viral extraction from cell culture16 Jun 2026US 12,655,397 B2National Research Council of Canada
- Oncolytic reovirus13 May 2025US 12,295,977 B2
- Vaccines against avian reoviruses14 Nov 2023US 11,813,321 B2Biomune Company
- Reoviruses having modified sequences15 Feb 2022US 11,246,930 B2Oncolytics Biotech Inc.
- Avian reovirus vaccines17 Aug 2021US 11,090,377 B2University of Georgia Research Foundation, Inc.
- Viral Extraction from Cell Culture13 Nov 2025US 2025/0346868 A1National Research Council of Canada
- Novel modified reovirus and use thereof8 Feb 2024US 2024/0041959 A1Virocure, Inc.
- Composition for preventing or treating inflammatory diseases of digestive system or colitis, comprising reovirus as active ingredient1 Jun 2023US 2023/0165916 A1Virocure, Inc.
- New vaccines against avian reoviruses7 Oct 2021US 2021/0308253 A1Biomune Company
- Improved Oncolytic Reovirus14 Jan 2021US 2021/0008136 A1
Most cited
By later US patents
- Reoviruses having modified sequences11US 7,803,385 B2Oncolytics Biotech Inc. · 2010
- Reovirus strain 2177 and vaccine containing same7US 5,525,342 AAkzo Nobel N. V. · 1996
- Reoviruses having modified sequences3US 8,691,241 B2Oncolytics Biotech Inc. · 2014
- Reoviruses having modified sequences1US 10,039,827 B2Oncolytics Biotech Inc. · 2018
- Avian reovirus vaccines1US 10,588,958 B2University of Georgia Research Foundations, Inc. · 2020